The objective of this study was to demonstrate the feasibility and efficacy of induction chemotherapy, surgery, and pathology-guided adjuvant therapy to treat transorally resectable squamous head and neck cancer. METHODS: Patients had squamous head and neck cancer that was resectable by the transoral route and advanced-stage disease (American Joint Committee on Cancer stage III-IV, T3-T4 tumors, and/or positive lymph nodes). They received treatment with weekly carboplatin at an area under the curve of 2, plus paclitaxel 135 mg/m 2 , and daily lapatinib 1000mg for 6 weeks followed by surgical resection. Pathology that revealed margins <5 mm, extracapsular extension, N2a of N2b lymph node status, perineural invasion, or lymphovascular space invasion resulted in adjuvant radiotherapy concurrent with weekly cisplatin. Pathology with N2c/N3 lymph node status or positive margins resulted in radiation with bolus cisplatin. The primary endpoint was the clinical response rate to induction chemotherapy, and a key secondary endpoint was feasibility. RESULTS: Toxicity was modest, and 37 of 40 patients completed study procedures as planned. The clinical response rate was 93%, the pathologic complete response rate was 36%, and the clinical response did not predict for a pathologic complete response. No patient on study follow-up has recurred or died. Twenty-nine of 39 patients who underwent surgery avoided radiation. Speech and swallowing function were well preserved. CONCLUSIONS: The study met both its primary efficacy endpoint and the secondary feasibility endpoint. Neoadjuvant, systemic therapy and surgical resection followed by risk-adapted adjuvant therapy resulted in high response rates and excellent long-term outcomes and should be further studied. Cancer 2018;124:2986-92.
INTRODUCTION
The treatment of locally advanced head and neck cancer has evolved substantially, with chemoradiotherapy offering an alternative to large, morbid surgical resections. More recently, transoral endoscopic head and neck surgery has offered select patients a less invasive surgical option with low morbidity, low blood loss, excellent functional and cosmetic outcomes, and rapid recovery. 1 This advance is particularly applicable to cancers of the oropharynx, which, in recent years, have been divided biologically into those driven by human papillomavirus (HPV) and those driven by smoking. 2 It has been demonstrated that patients with the former cancers have an excellent prognosis, leading to clinical research interest in decreasing the morbidity of therapy. Patients with the latter cancers have a poorer prognosis, leading to interest in intensifying therapy to improve the cure rate. However, stratification by HPV status is imperfect, with some HPV-driven cancers recurring and a significant proportion of smoking-related cancers achieving a cure.
Induction chemotherapy has been proposed for both of these populations with distinct rationales. For HPV-positive patients who have a good prognosis, induction has been evaluated with the goal of de-intensifying definitive radiation therapy for patients who have an excellent response. For those with a poorer prognosis, induction chemotherapy has been studied as an additive therapy to standard care treatment in an attempt to intensify therapy. The best studied regimen is the combination of cisplatin, docetaxel, and 5-fluorouracil; however, most studies have reported high rates of grade 3 and 4 toxicity, imperfect feasibility of subsequent definitive therapy, and a lack of improvement in survival. [3] [4] [5] [6] Prior retrospective 7 and prospective 8 phase 2 work indicates that both a complete pathologic response and long-term control are possible with chemotherapy alone in patients who have laryngeal cancer.
We hypothesized that an induction regimen with a high response rate and low toxicity could partner well with transoral endoscopic head and neck surgery and build on this prior work. Noting favorable results from phase 2 trials 9,10 and a retrospective study 11 using weekly carboplatin, paclitaxel, and cetuximab, we attempted to improve this regimen by substituting lapatinib for cetuximab with the hypothesis that adding HER2 inhibition would increase activity. We noted that transoral endoscopic head and neck surgery shares the same favorable attributes that attracted us to this weekly induction schedule-low morbidity, good efficacy, and quick recovery leading to high feasibility of any subsequent, required adjuvant therapy. Finally, although we were skeptical of a radiologist's ability to accurately define tumor margins postinduction on scans, we had greater faith in the ability of surgical pathology to detect viable malignancy. We hypothesized that surgical pathology would integrate pretreatment risk with the extent of risk reduction achieved through induction. We sought to use this risk modulation to de-intensify therapy for select patients, omitting adjuvant radiation and chemotherapy altogether for those with the lowest postinduction risk. By omitting radiotherapy when supported by pathologic results, we hoped to improve preservation of speech and swallowing function. For patients with higher risk, we hypothesized that the risk-adaptive approach would allow us to retain needed treatment intensity in the adjuvant setting, thus minimizing the risk of treatment failure.
MATERIALS AND METHODS

Ethics and Approvals
This study was approved by the Lineberger Comprehensive Cancer Center Protocol Review Committee and the University of North Carolina Institutional Review Board. It was conducted in accordance with the Declaration of Helsinki. The study was registered at clinicaltrials.gov (NCT01612351).
Study Design and Participants
Participants were required to have histologically defined squamous cell carcinoma of the head and neck of the following primary sites: oral cavity, oropharynx, larynx, and hypopharynx. Surgical resectability through the transoral route, as assessed by our surgeons, was required. Both HPV-positive and HPV-negative tumors were allowed. We required an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Adequate endorgan function was required, defined as an absolute neutrophil count 1500/mm 3 , platelets 100,000/mm 3 , hemoglobin >9 g/dL, total bilirubin <1.5 mg/dL, albumin >2.5 g/dL, aspartate and alanine aminotransferase levels 2.5 times institutional upper limit of normal, alkaline phosphatase <2.5 times the upper limit of normal, and glomerular filtration rate 40 mL/minute (by the standard Cockroft and Gault formula or measured by 24-hour urine collection). Left ventricular ejection fraction was required to be within normal limits. Any stage other than T1N0 or T2N0 was allowed.
Treatment Regimen
The general plan for treatment is shown in Figure 1 . The induction regimen consisted of carboplatin at an area under the curve of 2 and paclitaxel 135 mg/m 2 administered weekly concurrent with daily oral lapatinib at 1000 mg for 6 weeks. Procedures were available for gastrostomy-tube administration of lapatinib if needed. From 2 to 5 weeks after the completion of induction chemotherapy, imaging was performed for the primary endpoint of clinical response rate, and patients proceeded to transoral endoscopic head and neck surgery with neck dissection. Two senior surgeons with fellowship training in transoral endoscopic head and neck surgery either performed the surgery or were present as proctors during primary site resection. Surgery not only extirpated the cancer but also provided a study-defined, pathology-based risk level to determine the need for subsequent therapy. Patients who had a pathologic lymph node status of pN0 or pN1 were observed. Patients who underwent R1 resection, had extracapsular extension, had pN2a or pN2b lymph node status, or had perineural or lymphovascular space invasion received ipsilateral radiation to 60 gray (Gy) concurrent with weekly cisplatin at 30 mg/m 2 . We did not mandate treatment to the imaging-defined preinduction fields but, rather, specifically permitted narrowing of radiation fields based on pathologic data. Patients who had pN2c/pN3 lymph node status or grossly positive margins received cisplatin 100 mg/m 2 with bilateral radiation.
Statistics
The primary endpoint of the study was the clinical response rate, defined by Response Evaluation Criteria in Solid Tumor (RECIST) measurements before and after induction. By using a 2-stage design, we tested the null Risk-Adapted Induction/Weiss et al
Cancer
July 15, 2018 hypothesis that the clinical response rate (complete response plus partial response) to induction chemotherapy is 64% 5 against the 1-sided alternative that it is >64% (alternative hypothesis 5 80%). We specified that the induction regimen was to be considered successful if 30 of 40 patients responded. Power calculations were conducted using PASS statistical software (NCCS, LLC, Kaysville, Utah), which indicated that, if induction chemotherapy was not effective, then there was a .097 probability of concluding that it is effective; and that, if the induction chemotherapy actually was effective, then there was a .161 probability of concluding that it is not effective.
For the secondary endpoint of feasibility, we predetermined that, if at least one-half of patients completed all 3 parts, then the total treatment strategy would be considered feasible. For the secondary endpoint of risk reduction, patients were assigned a risk group based on their baseline characteristics. The percentage of patients whose risk level was successfully improved by induction chemotherapy is reported as the number of patients who successfully avoided radiation (based on stage III/IV study entry inclusion criteria, all patients were expected to require radiation). A pathologic complete response was defined as no viable cancer cells on surgical pathology; patients who had a near pathologic complete response (subcentimeter foci of cancer) were counted as nonresponders for this measure. Progression-free survival (PFS) and overall survival (OS) were calculated from the first treatment date.
PFS was based on progression, the last disease assessment, or death; and OS was based on the last contact or death. The Kaplan-Meier method was used to estimate median PFS and OS along with 95% confidence intervals (CIs). Kappa statistics were calculated for agreement between clinical and pathologic responses, and the Fisher exact test was used to evaluate associations of baseline risk level with response and postinduction risk level. All analyses were conducted using SAS statistical software version 9.4 (SAS Institute, Inc, Cary, NC).
RESULTS
In total, 40 patients were accrued between October 3, 2012 and August 23, 2016. Demographics of the sample are provided in Table 1 . It is noteworthy that 30 of 40 patients had oropharyngeal cancer; 17 of these patients (or greater than one-third of the overall cohort) had lowrisk HPV, as defined by the Radiation Therapy Oncology Group (RTOG). 2 Supporting Table 1 indicates that stage was relatively advanced: 20% of patients had stage III disease, and 80% had stage IV disease according to the American Joint Committee on Cancer Staging Manual (seventh edition). Most patients reached these stages because of their lymph node status; only 4 patients had primary T3 tumors, and 2 patients had primary T4 tumors.
Thirty-nine of 40 patients underwent surgery. One single patient who had a clinical complete response Original Article
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Cancer declined surgery for nontoxicity-related reasons, withdrew himself from the study entirely, and declined any definitive therapy despite clinical eligibility; data from this patient for toxicity and clinical response, which were available before withdrawal, are included. We are aware that this patient's cancer subsequently progressed and that he died. Thirty-seven of the remaining 39 patients completed 3-part therapy, thus the study met the prespecified criteria for feasibility. One patient who had close but negative margins had a delayed convalescence after induction therapy and surgery, which led her treating radiation oncologist to recommend against adjuvant therapy. We note that her cancer subsequently recurred and was treated with laryngectomy and adjuvant radiation. She died of pneumonia 18 months later without evidence of disease. Another patient did not adhere to study procedures because of psychiatric, nontoxicity-related reasons; and her treating clinician removed her from the study during follow-up. For this patient, data are available up to the tine she was removed from the study; she remains alive without evidence of disease.
The toxicity of induction therapy (all attributable grade 3-4 adverse events and attributable grade 1-2 adverse events that occurred in at least 10% of patients) is detailed in Table 2 . Three patients were hospitalized during induction chemotherapy. Generally, toxicity was mild. Diarrhea was the most common adverse event, as expected with lapatinib, occurring in 38% of patients at grade 1 and 2 and in 5% at grade 3 and 4. The study provided diarrhea management guidelines, which were successful. Neutropenia also was common at grade 1 and 2 in 18% of patients and at grade 3 and 4 in 38%. This resulted in frequent dose-holding, and 6 patients received filgrastim; these strategies were successful, because the febrile neutropenia rate was only 5%. The clinical response rate (the primary endpoint of the study) was 93%. The clinical complete response rate was 40%. A waterfall plot is provided in Figure 2 . We note that many patients who had a clinical complete response did not reach 100% because they had residual lymph nodes that longer reached pathologic dimensions. Fourteen of 39 patients (36%) had a pathologic complete response. Clinical response (j 5 .18; P 5 .8) was not associated with pathologic complete response. RTOG risk level did not predict for the clinical response rate (29% complete responses in the low-risk group vs 46% in the medium/high-risk group; P 5 .5) or the postinduction risk level (P 5 .9). We regard subgroup analyses in a phase 2 study like this with extreme caution and only as an exploratory analysis; individual patient data are provided in Supporting Table 2 to empower any calculations of interest. We note that only17 patients had RTOG lowrisk, HPV-positive disease; among these patients, the rate of pathologic complete response was 48% compared with 29% in all other patients (P 5 .3).
Seven patients entered with study-defined, low-risk disease; 25 entered with study-defined, medium-risk disease; and 7 entered with study-defined, high-risk disease. Five of 7 patients (71%) who had low-risk disease at entry remained in the low-risk group, 21 of 25 patients (84%) who had medium-risk disease at entry changed to the lowrisk group and thus avoided radiation, and 4 of 7 patients (57%) who had high-risk disease at entry changed to the low-risk group and thus avoided radiation. Therefore, in total, 30 of 39 patients (77%) who were projected to require postoperative radiation according to the standard of care were able to avoid it. Supporting Figure 1 illustrates the flow of patients, indicating prestudy risk levels on the x-axis and color-coded, pathologically defined risk levels.
At a median follow-up of 2.4 years (range, from 2 months to 4.6 years), no patient on study follow-up has recurred or died. PFS and OS curves, to indicate the extent of maturity and censoring, are provided in Figure 3 .
We followed changes in ECOG performance status, weight, swallowing (according to the MD Anderson dysphagia inventory 12 ), and voice (according to the voicerelated quality of life scale 13 ). For both quality-of-life (QOL) measures, scores range from 0 to 100, with higher scores indicating better QOL. Pretreatment to postinduction ECOG performance status was the same for almost every patient. Comparing performance status before treatment versus 1 year after surgery, 55% of patients had the same performance status, 6% declined from to 0 to 1, and 39% improved from 1 to 0. Weight was also well preserved, with a mean weight of 85.1 kg (95% confidence interval [CI], 79.6-90.7 kg) before induction, 84.7 kg (95% CI, 79.0-90.4 kg) after induction, and 83.4 kg (95% CI, 77.6-89.1 kg) 1 year after surgery. Patients who received radiation lost more weight between study initiation and 1 year postsurgery (mean weight loss, 7.9 kg; 95% CI, 12.2-3.6 kg) compared with those who did not receive radiation (mean weight loss, 1.3 kg; 95% CI, from 3.3 kg lost to 0.7 kg gained). Patients who had a pathologic complete response gained a mean of 0.8 kg (95% CI, from 1.4 kg lost to 3.0 kg gained) between study initiation and 1 year postoperatively, whereas those without a pathologic complete response lost a mean of 4.5 kg (95% CI, 7.0-2.0 kg). 
DISCUSSION
The current study met its primary endpoint of a clinical response rate of at least 80%, and the pathologic clinical response rate of 36% was unexpectedly favorable. Possible explanations for this include the activity of lapatinib, the activity of the cytotoxic backbone, and the risk level of the population accrued. Regarding lapatinib, we note that multiple clinical studies have been published between study inception and the current article that cast doubt on its activity. [14] [15] [16] Used as a single agent in metastatic/recurrent disease, the response rate was 0%. When combined with capecitabine in metastatic/recurrent disease, the outcome appeared to be similar to that expected with capecitabine alone. In a phase 3 study combined with chemoradiotherapy, lapatinib did not add benefit. Therefore, existing clinical data argue against a substantial contribution from lapatinib. Correlative analysis is planned to better understand any potential contribution from lapatinib in specific patients.
The population accrued herein was not high risk, but it also was not low risk. Most patients had advanced tumor and/or lymph node status. Although most enrolled patients had oropharyngeal cancer as a result of the inclusion criteria that required resectability via the transoral route, only 17 of 40 patients had biologically low-risk disease according to RTOG criteria. 2 In explaining these results, we attribute a dominant role to the activity of the weekly carboplatin and paclitaxel cytotoxic therapy. Multiple retrospective cohorts and phase 2 studies of similar regimens have been reported with high clinical response rates. Given the hazards of cross-trial comparisons, especially with regard to small phase 2 studies, we do not regard our results as substantially different from these. We do consider it novel that we have demonstrated a high pathologic complete response rate, 36%. Prior work in oral cavity cancer indicated a pathologic complete response rate of 13% to combined cisplatin, docetaxel, and 5-fluorouracil chemotherapy. 17 Although we view the complete response rate reported herein as strongly supportive of future studies of weekly carboplatin and taxane-based preoperative induction regimens, we caution against conflating the pathologic complete response rate with a cure. In addition to extirpating cancer in patients who have residual disease and defining the need for postoperative therapy, surgery also may have removed microscopic residual disease that was not detected by surgical pathology. With regard to toxicity and feasibility of subsequent therapy, regimens of weekly carboplatin and taxane appear to be favorable as backbones for combined studies with novel agents.
Outcomes in our study were excellent. Thirty of 39 patients did not receive adjuvant radiotherapy. The functional result was excellent, with speech, swallowing, weight, and performance status preserved. Deintensification of the radiation dose for HPV is a common clinical trial paradigm. For example, the ECOG 1308 trial 18 treated HPV-positive or p16-positive oropharyngeal squamous cell carcinoma with 3 cycles of induction cisplatin, paclitaxel, and cetuximab followed by dosereduced radiation (54 Gy) and cetuximab in patients who had a clinical complete response. Although we did not select for HPV in the current study, we note that 14 of 17 of our RTOG low-risk patients entirely avoided radiotherapy. Whereas some might be concerned that 3 RTOG low-risk patients received trimodality therapy, we note that cure rates even for RTOG low-risk disease are not perfect, yet none of the patients on this trial have had a recurrence. In contrast to the dominant approach for HPV-driven cancer, intensification is frequently discussed for HPVnegative cancer. However, studies with combined docetaxel, cisplatin, and 5-fluorouracil mostly have not improved outcomes. In the current study, no patient with non-RTOG, low-risk disease has recurred or died; 15 of 22 accomplished this with a 100% dose reduction (omission) of radiotherapy.
We do not believe that these results are practicechanging and did not intend them to be so at the time of study design. However, we do believe that these results can meaningfully impact future investigations. First, extensive biologic study will be required to better understand the drivers behind the high clinical and pathologic responses observed; such studies are planned. Second, although preoperative induction chemotherapy outside of oral cancer has rarely been studied, we believe that these results support such study. Finally, we believe that this study and others have demonstrated that regimens of carboplatin, a taxane, and a targeted therapy agent have high clinical activity, low toxicity, and high feasibility of subsequent therapy, justifying the use of this backbone for studies of novel agents. Doing so before surgery allows for an evaluation of pathologic response as well as paired correlative studies before and after treatment. We have initiated a study of weekly carboplatin, nanoparticle albumin-bound (nab)-paclitaxel, and the programmed cell death ligand 1 (PD-L1) inhibitor durvalumab (NCT03174275).
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